Sodium chloride

Octapharma USA Grant Supports PANS/PANDAS Education Event at NHIA Conference March 27 in Washington, D.C.

Retrieved on: 
Thursday, March 23, 2023
University of Arizona College of Medicine – Tucson, PANS, Janet Woodcock, Sodium chloride, Medical Affairs Bureau, University, Erythema ab igne, Octapharma, Encephalitis, DSM-IV codes, University of Arizona College of Pharmacy, Science, Patient, Immune system, Clutch (eggs), Diagnosis, Research, PANDAS, Conference, Strep, Pharmaceutical industry

The Octapharma educational grant supports the Immunoglobulin National Society (IgNS) breakfast symposium , "PANS/PANDAS in Children: Controversies, Evidence, Research and Treatment Guidelines for Challenging Cases," to be held Monday, March 27th at 7:30 a.m.

Key Points: 
  • The Octapharma educational grant supports the Immunoglobulin National Society (IgNS) breakfast symposium , "PANS/PANDAS in Children: Controversies, Evidence, Research and Treatment Guidelines for Challenging Cases," to be held Monday, March 27th at 7:30 a.m.
  • Rice, M.D., both of the University of Arizona College of Medicine Tucson and investigators leading the Octapharma PANS/PANDAS clinical trial.
  • "Octapharma is looking forward to sharing valuable information on PANS/PANDAS with NHIA attendees," said Octapharma USA President Flemming Nielsen.
  • For more study information, please contact Huub Kreuwel, Ph.D., Octapharma USA, Vice President of Scientific and Medical Affairs, at [email protected] or visit ClinicalTrials.gov (Identifier: NCT04508530).

Public Advisory - Two lots of cystic fibrosis drug Cayston recalled due to the potential of cracked glass vials

Retrieved on: 
Saturday, March 18, 2023
DIN, Sodium chloride, Sepsis, Abscess, Health status of Asian Americans, Urinary tract infection, Pharmacy, Patient, Risk, Cystic fibrosis, Health, Health Canada, Glass, Pneumonia, Pharmaceutical industry, Medical device, Aztreonam

Health Canada is advising the public that Gilead Sciences Incorporated recalled two lots (032168 and 033357) of the cystic fibrosis drug Cayston (aztreonam) (DIN 02329840) on March 1, 2023 , due to the potential of cracked glass vials in those lots, which may introduce glass particles into the medication.

Key Points: 
  • Health Canada is advising the public that Gilead Sciences Incorporated recalled two lots (032168 and 033357) of the cystic fibrosis drug Cayston (aztreonam) (DIN 02329840) on March 1, 2023 , due to the potential of cracked glass vials in those lots, which may introduce glass particles into the medication.
  • A cracked glass vial could cause potential injury or lead to potential contamination or a reduced dose.
  • Cayston is a prescription antibacterial medicine used for the management of chronic infections in cystic fibrosis patients.
  • The manufacturer has not received any customer complaints in relation to cracked glass vials in the recalled lots, or any other Cayston lots distributed in Canada.

ReSaltZ Shampoo Bar is Offering Zero-Waste Eco-Friendly Products for Sustainable Consumption

Retrieved on: 
Friday, February 24, 2023
Sodium chloride, Heart, UNESCO, Environment, Scalp, Mineral, Cosmetics, Guérande

Summary: ReSaltZ, a Korean skincare brand, is making strides in the skincare sector by offering products with zero-waste and eco-friendly properties.

Key Points: 
  • ReSaltZ offers strictly vegan formulated ingredients, zero-waste, environmentally friendly product range to help promote healthy skincare habits.
  • Hair Perfumed Conditioner Bar and Scalp Scaling Ritual Shampoo are two of the newest additions to the brand's product range and include all-natural ingredients.
  • ReSaltZ is also committed to producing zero waste by using only recyclable and reusable packaging for all their products.
  • By reducing waste, ReSaltZ is helping customers to lessen their impact on the environment, enabling sustainable beauty.

Global Reduced Salt Food Products Market Report 2022 to 2028: Featuring General Mills, Nestle, PepsiCo and Hormel Foods Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023
Food, Beverage, Retail, Intussusception (medical disorder), Stomach cancer, Sodium chloride, Stroke, Lethargy, Meat, Kidney disease, Health, Hyponatremia, Blood, Vegetable, Cell, Heart failure, Water, COVID-19, Mental toughness, Egg, Meal, Cooking, Market, Osteoporosis, Eating, World Health Organization, Diet, Drinking, Risk, Sodium, Poultry, Salt, Dietary supplement

The "Global Reduced Salt Food Products Market Size, Share & Industry Trends Analysis Report by Type, Distribution Channel, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Reduced Salt Food Products Market Size, Share & Industry Trends Analysis Report by Type, Distribution Channel, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Reduced Salt Food Products Market size is expected to reach $431.1 billion by 2028, rising at a market growth of 5.0% CAGR during the forecast period.
  • It is naturally present in foods like vegetables and eggs, as well as being a significant part of table salt (sodium chloride).
  • The reduced salt food products market was also impacted due to the closure of manufacturing facilities.

The Worldwide Reduced Salt Food Products Industry is Expected to Reach $431.1 Billion by 2028

Retrieved on: 
Sunday, January 22, 2023
Intussusception (medical disorder), Stomach cancer, Sodium chloride, Stroke, Lethargy, Meat, Kidney disease, Health, Hyponatremia, Blood, Vegetable, Cell, Heart failure, Water, Food, COVID-19, Mental toughness, Egg, Meal, Cooking, Market, Osteoporosis, Eating, World Health Organization, Diet, Drinking, Risk, Sodium, Poultry, Salt, Dietary supplement

The "Global Reduced Salt Food Products Market Size, Share & Industry Trends Analysis Report by Type, Distribution Channel, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Reduced Salt Food Products Market Size, Share & Industry Trends Analysis Report by Type, Distribution Channel, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Reduced Salt Food Products Market size is expected to reach $431.1 billion by 2028, rising at a market growth of 5.0% CAGR during the forecast period.
  • The reduced salt food products market was also impacted due to the closure of manufacturing facilities.
  • As a result, rising consumer awareness of the negative effects of high sodium intake as well as a growing desire for nutrient-dense, healthier food products is driving the reduced salt food products market.

Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Retrieved on: 
Wednesday, January 18, 2023
Mental Health, Research, Biotechnology, Other Health, Alternative Medicine, Health, Pharmaceutical, General Health, Science, Inc., Brain, Key finding attacks, Psychedelic drug, PRV, NEO, Biomarker, TD, Ketamine, NYSE, Feasibility study, Central nervous system, Food, Feasibility, PR, Consciousness, Deltoid muscle, Sodium chloride, Pharmaceutical industry, Medical imaging, Kernel

Results from this Cybin-sponsored study are intended to inform the future pathway for this program.

Key Points: 
  • Results from this Cybin-sponsored study are intended to inform the future pathway for this program.
  • “The results from the feasibility study are very promising and provide further insights into the potential of this cutting-edge wearable technology to quantify neural activity and changes in brain biomarkers during the administration of psychedelics.
  • Key Findings from the Feasibility Study:
    Demonstrated ketamine-induced changes to functional brain biomarkers associated with potential therapeutic effects, including alterations in cortical function associated with psychedelic experiences.
  • The feasibility study received U.S. Food and Drug Administration Investigational New Drug authorization in October 2021 and U.S. Institutional Review Board approval in January 2022.

Water softener market size to grow by USD 879.16 million from 2022 to 2027: A descriptive analysis of customer landscape, vendor assessment, and market dynamics - Technavio

Retrieved on: 
Monday, January 9, 2023
Projection, USD, Honeywell, Growth, RO, POE, Housing, Soil, Congestion, Sodium chloride, Salt, Nutrient, Water softening, Analysis, Culligan, Environment, Unilever, DIR, Perla, Market share, Water, Whirlpool Corporation, Plant, Hardness, 3M, POU, Groundwater, Urbanization, KENT, Regeneration, Fertilizer, Thermoplastic, Agriculture, Millennials, Geography

Vendor Landscape - The global water softener market is fragmented, with the presence of several global as well as regional vendors.

Key Points: 
  • Vendor Landscape - The global water softener market is fragmented, with the presence of several global as well as regional vendors.
  • By geography, the global water softener market is segmented into North America, Europe, APAC, South America, and the Middle East and Africa.
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global water softener market.
  • Major challenges - The threat to the environment due to salt-based water softener systems is a major challenge for the global water softener market growth.

Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Retrieved on: 
Tuesday, December 20, 2022
Biotechnology, Pharmaceutical, Health, Degenerative disease, Security (finance), Bromide, Patient, Central nervous system, Annual report, NYSE, Food, Common stock, Federation, Growth, SVP, COVID-19, Risk, Medication, Generic, FDA, Weather, Nasal spray, Amneal Pharmaceuticals, Sodium chloride, Tachycardia, Investment, Research, Abbreviated New Drug Application, Regulation of tobacco by the U.S. Food and Drug Administration, Pharmaceutical industry, Risk management

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the Company has successfully launched 26 new generic products in 2022.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the Company has successfully launched 26 new generic products in 2022.
  • Looking to 2023, we expect more than 30 new product launches,” said Chirag Patel and Chintu Patel, Amneal Co-Chief Executive Officers.
  • In addition, Amneal also announced it received Abbreviated New Drug Application approval from the U.S. Food and Drug Administration (“FDA”) for its first large volume bag, esmolol hydrochloride in sodium chloride injection.
  • According to IQVIA®, U.S. annual sales for this product for the 12 months ended October 2022 were $57 million.

Capstone Announces Authorization of Biosimilar Human Insulin for IV Infusion in Canada and EU

Retrieved on: 
Tuesday, November 29, 2022
Blood, Insulin, European Medicines Agency, Food, European Directive on Traditional Herbal Medicinal Products, Health Canada, Hospital, Partnership, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Committee for Medicinal Products for Human Use, Glucose, FDA, Liver, CHMP, Committee, Sodium chloride, IV, Celerity, Medical device, Pharmaceutical industry, Capstone, EU

ROSEMONT, Ill., Nov. 29, 2022 /PRNewswire/ -- Capstone Development Services Company LLC ("Capstone") announced today that a biosimilar version of human insulin received authorization from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) and a Notice of Compliance from Health Canada. The product is the only ready-to-use insulin for IV infusion. It received approval from the U.S. Food and Drug Administration (FDA) in 2019.

Key Points: 
  • ROSEMONT, Ill., Nov. 29, 2022 /PRNewswire/ -- Capstone Development Services Company LLC ("Capstone") announced today that a biosimilar version of human insulin received authorization from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) and a Notice of Compliance from Health Canada.
  • The product is the only ready-to-use insulin for IV infusion.
  • The ready-to-use insulin is formulated as an IV infusion in a flexible plastic container using human insulin in 0.9% Sodium Chloride injection to be administered to patients in hospitals and other acute care settings.
  • To date, Capstone has developed and gained regulatory approvals on 18 products in the U.S., EU and Canada.

Nick Stenson Beauty to Launch New Line at Ulta Beauty in November

Retrieved on: 
Wednesday, November 2, 2022
Home Goods, Cosmetics, Retail, Women, Seniors, Online Retail, Luxury, Teens, Men, Department Stores, Bridal, LGBTQ+, Specialty, Family, Consumer, Fashion, Animal, Life, Conditioner, Lingo (VoIP Service operator), Ulta Beauty, Industry, Travel, Collection, Empowerment, Ulta, Sodium chloride, Beauty, Education, Creatine, Social media, Paraben, Nutrient, Skin, Hair, Aloe vera, NICK, Multimedia, Jojoba oil, B-12, Antioxidant, Internet, Senior, Stenson, Cosmetics

(Photo: Nick Stenson Beauty)

Key Points: 
  • (Photo: Nick Stenson Beauty)
    The line was created by award-winning global hair stylist and beauty industry leader Nick Stenson, whos passion for beauty is rooted throughout his extensive career.
  • WHAT NICK STENSON BEAUTY IS MADE OF: ALOE VERA, CREATINE + MORE
    All products in the Nick Stenson Beauty hair care collection contain Aloe Vera Gel as the key ingredient.
  • For more tips, how-to demos and ingredient information follow Nick Stenson (@nickstenson) and Nick Stenson Beauty (@nickstensonbeauty), and be fully immersed in the Consciously Curated, Naturally Luxe Nick Stenson Beauty experience.
  • ABOUT NICK STENSON BEAUTY: Nick Stenson Beauty (@nickstensonbeauty) is where nature meets luxury.